Advertisements


Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results

SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Mateon.....»»

Category: earningsSource: benzingaApr 16th, 2018

Entasis Therapeutics Reports Full Year 2018 Financial Results and Provides Business Update

WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a.....»»

Category: earningsSource: benzingaMar 29th, 2019

Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued.....»»

Category: earningsSource: benzingaMar 28th, 2019

CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported its financial res.....»»

Category: earningsSource: benzingaMar 18th, 2019

Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developin.....»»

Category: earningsSource: benzingaMar 14th, 2019

Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass., M.....»»

Category: earningsSource: benzingaMar 11th, 2019

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

-First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta t.....»»

Category: earningsSource: benzingaFeb 25th, 2019

Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019

CRANBURY, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the "Company") to.....»»

Category: earningsSource: benzingaFeb 14th, 2019

Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018

CRANBURY, N.J., .....»»

Category: earningsSource: benzingaDec 18th, 2018

Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results

WARREN, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the thi.....»»

Category: earningsSource: benzingaNov 7th, 2018

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results

-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD--Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018--Preclinical Studies for CTX110 Targeting CD19+ Malignancies Ha.....»»

Category: earningsSource: benzingaAug 7th, 2018

Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results

WARREN, N.J., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ.....»»

Category: earningsSource: benzingaAug 1st, 2018

Unum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

– Successfully Completed IPO and Concurrent Private Placement Raising $77 Million in Gross Proceeds – – Initiated Cohort Expansion of ATTCK-20-2 Phase I T.....»»

Category: earningsSource: benzingaMay 14th, 2018

Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update

NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial re.....»»

Category: earningsSource: benzingaMay 11th, 2018

Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

WARREN, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today prov.....»»

Category: earningsSource: benzingaMay 10th, 2018

Net Element Reports Full-Year 2018 Financial Results and Provides Business Update

Net Element Reports Full-Year 2018 Financial Results and Provides Business Update.....»»

Category: earningsSource: benzingaApr 1st, 2019

CollPlant Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update

CollPlant Reports Fourth Quarter and Year End 2018 Financial Results and Provides Business Update.....»»

Category: earningsSource: benzingaApr 1st, 2019

TCR2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today reported financial re.....»»

Category: earningsSource: benzingaApr 1st, 2019

TLC Reports Fourth Quarter and Full Year 2018 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 01, 2019 (GLOBE NEWSWIRE) -- TLC (NASDAQ:T.....»»

Category: earningsSource: benzingaApr 1st, 2019

Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update

LOS ANGELES, March 29, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointe.....»»

Category: earningsSource: benzingaMar 29th, 2019

OSE Immunotherapeutics Reports 2018 Financial Results and Business Update

Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseases OSE's partnership business model based on innovative products; Multiple validating partnering milestones generated €35 milli.....»»

Category: earningsSource: benzingaMar 28th, 2019